ArticleScientific reports2018
Carbapenem Nonsusceptible Klebsiella pneumoniae in Taiwan: Dissemination and Increasing Resistance of Carbapenemase Producers During 2012-2015.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Multidrug-resistantNew microbes and new infections · 2026Article
- Epidemiology and Genetic Traits of Carbapenemase-Producing Enterobacterales: A Global Threat to Human Health.Antibiotics (Basel, Switzerland) · 2025Review
- Review
- Genome Sequencing and Comparative Genomic Analysis of Multidrug-ResistantInfection and drug resistance · 2025Article
- Emergence and transmission of the high-risk ST78 clone of OXA-48-producingEmerging microbes & infections · 2024Article
- Antimicrobial resistance, biofilm formation, and molecular detection of efflux pump and biofilm genes amongHeliyon · 2024Article
- Identification of a Novel KPC Variant, KPC-204, Conferring Resistance to Both Carbapenems and Ceftazidime-Avibactam in an ST11Microorganisms · 2024Article
- Article
- Molecular and Clinical Characteristics of Carbapenem-ResistantInfection and drug resistance · 2023Article
- Multi Evaluation of a Modified GoldNano Carb Test for Carbapenemase Detection in Clinical Isolates of Gram-Negative Bacilli.Antibiotics (Basel, Switzerland) · 2022Article
- Molecular Epidemiology, Risk Factors and Clinical Outcomes of Carbapenem-NonsusceptiblePathogens (Basel, Switzerland) · 2022Article
- A Longitudinal Nine-Year Study of the Molecular Epidemiology of Carbapenemase-ProducingFrontiers in microbiology · 2022Article
- Detection of blaKPC and blaNDM carbapenemase genes among Klebsiella pneumoniae isolates in Addis Ababa, Ethiopia: Dominance of blaNDM.PloS one · 2022Article
- Synergistic Combination of AS101 and Azidothymidine against Clinical Isolates of Carbapenem-ResistantPathogens (Basel, Switzerland) · 2021Article
- Evaluation of the Organotellurium Compound AS101 for Treating Colistin- and Carbapenem-ResistantPharmaceuticals (Basel, Switzerland) · 2021Article
- In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.The Journal of antimicrobial chemotherapy · 2021Article
- Characterization of resistance mechanisms of Enterobacter cloacae Complex co-resistant to carbapenem and colistin.BMC microbiology · 2021Article
- Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-NonsusceptibleAntimicrobial agents and chemotherapy · 2021Article
- Colonization Dynamics of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Increasing New Delhi metallo-β-lactamase-positive Escherichia coli among carbapenem non-susceptible Enterobacteriaceae in Taiwan during 2016 to 2018.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Before 2011, the prevalence rates of carbapenemase-producing Klebsiella pneumoniae (CPKP) among carbapenem nonsusceptible K. pneumoniae (CnSKP) isolates were below 10% in Taiwan. The study presents the dissemination and increased antimicrobial resistance of CPKP from January 2012 to August 2015, as shown by Taiwanese multicenter surveillance. Isolates with minimum inhibitory concentrations (MICs) of >1 μg/mL for imipenem or meropenem were collected, screened for various carbapenemase genes by PCR, and tested for antimicrobial susceptibility. Among 1,457 CnSKP isolates, 1,250 were collected from medical centers. The CnSKP prevalence in medical centers increased by 1.7-fold during the study. Among all CnSKP isolates, 457 were CPKP. The CPKP rate among CnSKP increased by 1.5-fold and reached 36.8% in 2015. The CPKP nonsusceptibility rate to aztreonam, fluoroquinolones, and aminoglycosides increased yearly. Six CPKP isolates carried dual carbapenemase genes. Three Ambler classes were identified in 451 isolates with a single carbapenemase: classes A (315 bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.